



FIRST INTERNATIONAL  
CONGRESS OF  
**BIOIMMUNOTHERAPY**  
OF CANCER

*An International multidisciplinary meeting*

*Responsabile Scientifico:*

**Dr. Pierpaolo Correale**

12-13-14  
APRILE 2019

REGGIO CALABRIA  
ITALY

Palazzo della Provincia, Sala Perri, Piazza Italia,  
89125 Reggio Calabria



# RATIONALE

New management strategies and newest treatment modalities are rapidly entering in the clinical practice of cancer patients leading to an unexpected improvement in quality of life and survival.

In particular, Clinical development of Small molecules with specific molecular targets, immune-ontological treatments and combined treatments are completely changing the way we see and treat some of the most the most common malignancies including Non small cell lung cancer, breast cancer, gastroenteric malignancies, genitourinary and gynecological malignancies, and malignant melanoma.

However, the correct use of these innovative strategies and treatments requires a specific multi-disciplinary approach, modern management procedures, and a rising knowledge of anticancer pharmacology, cancer- and immune-associated molecular biology, immune-oncology, and radiobiology. This meeting highlights the baseline professional needs for a correct diagnosis, care and treatment of these patients at any stage of disease with a prospect of future directions. An international team of scientist and academics will contribute to enhance the skills of people who operate in the management of these patients and in the designs of innovative treatment strategies for advanced disease and to define the mechanisms of action and the rationale behind the most innovative strategies.

## PRESIDENT

Pierpaolo Correale

## HONORARY PRESIDENTS

Michail Sitkovsky, Luigi Pirtoli, Antonio Giordano, Michele Caraglia

## COPRESIDENT

Pierosandro Tagliaferri e Pierfrancesco Tassone

## SCIENTIFIC SECRETARY STAFF

Rita Agostino, Domenico Azzarello, Giuseppe Bellocco, Caterina Giuffrè, Antonino Mafodda, Roberto Maisano, Giovanna Orizzonte and Vincenzo Panuccio

## SCIENTIFIC COMMITTEE

Kwong Yok Tsang, Rocco Giannicola, Pietro del Medico and Fiorella Guadagni

## SCIENTIFIC SECRETARY BOARD

Antonella Falzea, Mariangela Polifrone

APRIL, FRIDAY 12TH, 2019

Ore 8.30 Authority salutation

Vice-Ministro dell'economia, *Onorevole Senatore Massimo Garavaglia*

Autorità regionali

Autorità Città Metropolitana

Direzione Strategica Grande ospedale Metropolitano

Associazione Salus Donna: *Anna Mancuso*

Associazione ARCO: *Francesco Provenzano*

Ore 9.30 INTRODUCTION:

*Prof. Angelo Raffaele Bianco, Prof. Luigi Pirtoli, Prof. Pierosandro Tagliaferri,*

*Dr. Pierpaolo Correale*

## GENERAL SESSION

### STANDARD CARE AND PATIENT MANAGEMENT

*(Lingua ufficiale Italiano):*

CHAIRMEN: *Mario Roselli and Sabino de Placido*

Ore 9.45 / *Ettore Jorio*

Interrelazione ospedale territorio

Ore 10.00 / *Fiorella Guadagni*

Dalle Banche dati alla pratica clinica

Ore 10.15 / *Claudio Verusio*

Il passo dalla diagnosi alla presa in carico della "persona" paziente

Ore 10.30 / *Pierpaolo Correale*

Real World Evidence in Oncologia

Ore 10.45 / *Salvatore Palazzo*

Sostenibilità dei nuovi trattamenti, reperimento e razionalizzazione delle risorse

Ore 11.00 / *Giovanna Chiappetta*

Il consenso informato: tutela del paziente o difesa del medico

Ore 11.15 / *Antonio Giordano*

Le collaborazioni internazionali; formazione e leadership

Ore 11.30 / *Stefano Magrini*

Riorganizzazione della rete radioterapica regionale

**Ore 11.45 / *Giovanna Malara***

Un modello di integrazione multi-disciplinare complessa nella diagnosi e cura del melanoma maligno; target therapy e immunocheckpoint

**Ore 12.00 / *Rocco Giannicola***

Organizzazione, attrezzatura e necessità irrinunciabili per la creazione di una lung unit efficiente

**Ore 12.15 / *Antonio Santo***

Una forza nazionale integrata contro il carcinoma polmonare

**Ore 12.45 / *Guido Francini***

L'Oncologia nel paziente anziano

**Ore 13.00 / *Mariangela Polifrone***

La valutazione psiconcologica del paziente con carcinoma polmonare

**LUNCH**

---

## **Bio-immunotherapy congress**

*(Lingua ufficiale Inglese):*

WORK OPENING: *Luigi Pirtoli, Pierosandro Tagliaferri, Pierpaolo Correale*

## **I SESSION**

### **ADVANCEMENT FOR GENITOURINARY MALIGNANCIES**

CHAIRMEN: *A Madan Ravi, Guido Francini*

**Ore 15.00 / *Francesco Grillone***

Hormonal therapy evolution in prostate cancer

**Ore 15.15 / *Edoardo Francini***

Role of chemotherapy in prostate cancer

**Ore 15.30 / *Paolo Tini***

Salvage radiotherapy for prostate cancer; potential predictive immunological parameters of response

**Ore 15.45 / *Camillo Porta***

Kidney Cancer molecular definition, inheritance and treatment implications

**Ore 16.00 / *Giacomo Carteni***

TKI, mTOR inhibitors and anti-angiogenic mAbs in kidney cancer

**Ore 16.15 / Rita Agostino**

Kidney cancer a long lasting model for cancer immunotherapy: from the interleukin 2 to the immune-check point inhibitors

**Ore 16.30 / Antonino Mafodda**

Chemotherapy or immune-check point blockade in the savage treatment of metastatic urological malignancies

---

## **II Active specific Immunotherapy and immune-checkpoint inhibitors in Malignant melanoma, and Head and Neck Carcinoma (HNC)**

CHAIRMEN: *Stefano Magrini*

**Ore 17.00 / Grazia Cusi**

Viral infections and HNC: Risks and perspectives

**Ore 17.15 / Marta Maddalo**

Combined treatments for locally advanced head and neck cancer: the changing role of cetuximab and the new research avenues

**Ore 17.30 / Michele Del Vecchio**

Development of Target therapy in the treatment of malignant melanoma

**Ore 17.45 / Paola Queirolo**

Immuno-check point inhibitors in the treatment of malignant melanoma: the state of art

**Ore 18.00 / Paolo Pedrazzoli**

Vaccine and adoptive therapy in HNC

**Ore 18.15 / Rita Chiari**

New targets for non small cell lung cancer

**Ore 18.30 / Carmen Tebala**

Radiological evaluation of Head and neck cancer and malignant melanoma patients receiving Immunological treatments

## **Conclusions of the day**

**Ore 20.30 DINNER**

APRIL, SATURDAY 13TH, 2019

### III Immuno-oncological development and controversies (II)

CHAIRMEN: *Jay Berzowsky*

**Ore 8.30 / *M. Sitkovsky***

Critical role of hypoxia and cancer associated inflammation

**Ore 8.45 / *Robert M Hoffman***

Animal models and immunolo-oncological research

**Ore 9.00 / *Jack Greiner***

Basic principles of immunotherapy, cancer vaccines, co-accessory molecules

**Ore 9.15 / *Jay Berzowsky***

Active specific immunotherapy Translation from mice to human clinical trials

**Ore 9.30 / *A. Madan Ravi***

Immuno-oncological treatments for prostate carcinoma future directions

**Ore 9.45 / *Massimo Di Maio***

History and clinical development of therapeutic immune-checkpoint blockades; future challenges

**Ore 10.00 / *Vincenzo Desiderio***

Endoplasmic stress as a new target for anticancer therapies and immunological treatments

**Ore 10.15 / *Fabio Malavasi***

Interplay between Fc domain of therapeutic antibodies and specific receptors on different effector populations

**Ore 10.30 / *Claudio Tripodo***

Mechanism of failure of immune-checkpoints: effector failure or tumor resistance

**Ore 10.45 / *K kosmatopoulos***

There still a role for cancer vaccine?

**Ore 11.00 / *Bruno Cadilha***

Chemokine receptors enable adoptive T cell therapy homing into solid tumors

**Ore 11.15 / *Sonia Quarantino***

Immunomodulation in cancer beyond PD-1 and PD-L1

**Ore 11.30 / *Takuia Tsunoda***

The new generations of immunecheckpoint inhibitors

**Ore 11.45 / *Pierpaolo Correale***

PD-1 blockade: Antigen cascade, Autoimmunity and Major Histocompatibility Complex -

**COFFEE BREAK**

---

## **IV Immuno-oncological development and controversies (neoantigens, immunopriming and monoclonal antibodies)**

CHAIRMEN: *Kwong Yok Tsang and Fabio Malavasi*

**Ore 12.00 / *Pierfrancesco Tassone***

Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Human Malignancies

**Ore 12.15 / *Kwong Yok Tsang***

Mechanisms of action of a neoantigen-targeting antibody NEO-201

**Ore 12.30 / *Alfredo Colombo***

ADCC : from bench to bedside

**Ore 12.45 / *Massimo Fantini***

An IL-15 superagonist, ALT-803 enhances antibody-dependent cell-mediated cytotoxicity (ADCC) elicited by the novel monoclonal antibody NEO-201 against human carcinoma cells

**Ore 13.00 / *Christina Messineo Annunziata***

Immunotherapy in the treatment of gynecological malignancies

**Ore 13.15 / *Caterina Alati***

New moAbs in the treatment of acute leukemia

**Ore 13.30 / *Phil Arlen***

New antibodies in the treatment of bilio-pancreatic cancer

**Ore 13.45 LUNCH**

---

## **V Lung Cancer**

CHAIRMEN: *Piero Paladini, Baldo Mondello*

**Ore 14.30 / *Luca Luzzi***

Role of surgery and combined approach: neoadjuvant chemoradiotherapy and radio-immunotherapy

**Ore 15.00 / *Marta Castiglia***

Liquid biopsy and precision medicine

**Ore 15.15 / *Nadia Pasinetti***

Target therapy on drivers mutations

**Ore 15.30 / *Roberto Bianco***

Targeting EGFR pathway as treatment of non small cell lung cancer

**Ore 16.00 / *Vito Barbieri***

The Advent of immunotherapy from now to the future

**Ore 16.15 / *Rocco Giannicola***

Care and monitoring of NSCLC patient in treatment with immune-checkpoint blockade: iRAEs Pain, Emesis, Infection, and quality of life

**Ore 16.30 / *Pierpaolo Pastina***

Radiotherapy, new perspective and immunobiological effects

**Ore 16.45 / *Valerio Nardone***

Immune-checkpoint blockade Response evaluation by Digital analysis

**Ore 17.00 / *Luca Volterrani***

Radiological and clinical evaluation of Lung Cancer patients treated with immunotherapy or target therapy

---

## **VI Immuno-oncological development and controversies on adoptive therapy and micro RNA**

CHAIRMEN: *Massimo Martino and Bruno Martino*

**Ore 17.15 / *Massimo Martino***

Donor lymphocyte infusions in AML and MDS?

**Ore 17.30 / *Giulia Pucci***

Processing CSE toward Jacie accreditation

**Ore 17.45 / *Patrizia Comoli***

T cell therapy for viral infections

**Ore 18.00 / *Ciro Botta***

Immunobiological characterization of Tumor infiltrating lymphocytes derived from multiple myeloma patients



Ore 18.15 / *Marco Rossi*

Car-T based immunotherapy and adoptive therapy

Ore 18.30 / *Michele Caraglia*

Micro-RNAs and long non coding RNAs loops in human cancers: a new deal in anti-cancer treatment and immunotherapy

## Take the message round table

DISCUSSION LEADERS: *Chairmen: Massimo Martino and Bruno Martino*

APRIL, SUNDAY 14TH, 2019

## VII Advancement in Gastro-enteric malignancies

CHAIRMEN: *Antonio Russo, Gianfranco Filippelli*

Ore 9.00 / *Candida Mastroianni*

Anti-angiogenic treatments in gastro-enteric malignancies

Ore 9.15 / *Martinelli Erika*

Ore 9.30 / *Pierpaolo Pastina*

Effects of inflammatory status and k-ras mutation on patients response to the thymidylate synthase poly-epitope peptide vaccin

Ore 9.45 / *Teresa Troiani*

Immune-check point blockade and EGFR inhibition in advanced colorectal cancer; present and future directions

Ore 10.00 / *Pierosandro Tagliaferri*

Chemo-immunotherapy of Colorectal cancer; fifteen years of GOLFIG experience

---

## VIII session – Advancement in gynecological malignancies and breast cancer

CHAIRMEN: *Sandro Pignata and Serafino Conforti*

Ore 10.15 / *Stefano Palomba*

Surgery and combined therapeutic approaches to ovary and endometrial cancer

Ore 10.30 / *Sandro Pignata*

From the anti-blastic drugs to PARP inhibitor

**Ore 10.45 / *Pietro del Medico***

Chemo-immunological treatments of gynaecological malignancies

**Ore 11.00 / *Paolo Vigneri***

New pathways for breast cancer treatment; from bench to the bedside and vice-versa

**Ore 11.15 / *Salvatore Vaccarella***

Il ruolo della medicina di precisione nella pratica oncologica

**Ore 11.30 / *Carmelo Tuscano***

Radiotherapy and Cervical carcinoma, role of integrated treatments

**Ore 11.45 / *Roberto Maisano***

The unstoppable advent of cycline inhibitors

**Ore 12.00 / *Francesca Di Rella***

NPDL-1 blockade in the treatment of triple negative breast cancer

**Ore 12.15 / *Michele Caruso***

The new directions of cycline inhibitors

**Congress conclusions and salutations:**

**Michail Sitkovsky, Pierosandro Tagliaferri, Pierpaolo Correale**

# FIRST INTERNATIONAL CONGRESS OF BIOIMMUNOTHERAPY OF CANCER

*An International multidisciplinary meeting*

**12-13-14 APRILE 2019 | REGGIO CALABRIA, ITALY**

Responsabile Scientifico: **Dr. Pierpaolo Correale**

Il convegno è stato accreditato su Agenas, ha ottenuto i seguenti crediti formativi:

**12 Aprile** 2019 id 5090 - 253291 crediti assegnati N. **4.9**

**13 Aprile** 2019 id 5090- 253313 crediti assegnati N. **6.3**

**14 Aprile** 2019 id 5090- 253324 crediti assegnati N. **2.1**

Il convegno e' rivolto a N. **150** partecipanti PROVENIENZA REGIONALE

PROFESSIONE: MEDICO CHIRURGO

Discipline in: Allergologia ed immunologia clinica; anatomia patologica; chirurgia generale; chirurgia toracica; dermatologia e venereologia; ematologia; genetica medica; medicina generale (*medici di famiglia*); medicina interna; oncologia; radioterapia; urologia.

PROFESSIONE: INFERMIERE

Discipline in: Infermiere

PROFESSIONE: BIOLOGO

discipline in: Biologo

PROFESSIONE: FARMACISTA

discipline in: Farmacia ospedaliera; farmacia territoriale;

Tipologia evento: CORSO DI AGGIORNAMENTO

Obiettivi dell'Evento: LINEE GUIDA - PROTOCOLLI - PROCEDURE

## **CORSO GRATUITO**

L'iscrizione è gratuita e può essere effettuata tramite e-mail all'indirizzo: [xeniaeventi@gmail.com](mailto:xeniaeventi@gmail.com), allegando i dati anagrafici o telefonare al numero **0984.444890**

PROVIDER E SEGRETERIA ORGANIZZATIVA



# XENIA

WE DEVELOP YOUR IDEAS

**Xenia S.a.s.** di Francesca Mazza & C.

Via G. Verdi, 144 - 87036 Rende CS

Tel. **0984 444 890** - Cell. **3441872101**

E-mail: [xeniaeventi@gmail.com](mailto:xeniaeventi@gmail.com) | Id Provider **5090**

Patrocinio concesso da



L' Iniziativa è stata realizzata grazie al supporto incondizionato di:



**Bristol-Myers Squibb**

